


RxSight, Inc. (RXST)

Nasdaq; healthcare; SIC 3851, Ophthalmic Goods; CIK 0001111485

RxSight, Inc. RXST; healthcare	
Grade	A  strongest fifth of 371 graded peers percentile 16.2; sampling error 2.5 points; lower is stronger
Rank	61 of 371
Profitability	D  percentile 63.6
Solvency	B  percentile 23.0
Growth and financing	A/B  percentile 21.8
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$120M to \$591M assets total assets \$311.8M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active; fortress balance sheet
Inputs computable	9 of 14
Graded from	filings received through Feb 25, 2026 226 days before the rescans; latest periodic filing 10-Q received Aug 5, 2026
Last close	\$4.86 2026-10-08; market equity \$201.9M
Price used in grade	None



A, the bull
strongest fifth of its sector;
letters are fifths of the 371
graded peers

Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: A from Mar 21, 2025

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 25, 2026

RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device ("LDD?") and related accessories.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 63.6						
Gross profitability		33.0%	32.2%	43.7	372	2025-12-31
Return on invested capital		not computable	9.3%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Accruals ratio		(7.4%)	(6.6%)	52.5	811	2025-12-31
Gross margin stability, five years		20.5 pts	2.8 pts	94.6	243	2025-12-31
Solvency, sleeve percentile 23.0						
Twelve-month failure probability		0.06%	0.07%	38.5	248	2026-06-30
Altman Z double-prime		5.56	(0.31)	16.6	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000
Interest coverage		not computable	(4.51x)			interest expense must exceed \$100,000
Current ratio		10.95x	2.96x	14.0	839	2025-12-31
Growth and financing, sleeve percentile 21.8						
Revenue growth, three-year compound		40.0%	10.0%	16.9	415	2025-12-31
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		27.6%	2.1%	16.6	704	2025-12-31
Net share issuance, one year		1.9%	2.5%	31.8	634	2026-02-18


Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Fortress balance sheet	cash minus debt is 9,692,000 USD; Altman Z is not used

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
56	Harrow, Inc. (HROW)	14.9	A	late filer
57	Edwards Lifesciences Corp. (EW)	15.1	A	
58	Vertex Pharmaceuticals Inc. MA (VRTX)	15.4	A	
59	CareDx, Inc. (CDNA)	15.7	A	
60	Ensign Group, Inc. (ENSG)	15.9	A	fortress
				balance sheet
61	RxSight, Inc. (RXST) <	16.2	A	fortress
				balance sheet
62	Definium Therapeutics, Inc. (DFTX)	16.5	A	dilution
63	Natures Sunshine Products Inc. (NATR)	16.8	A	fortress
				balance sheet
64	Alnylam Pharmaceuticals, Inc. (ALNY)	17.0	A	
65	Aurinia Pharmaceuticals Inc. (AUPH)	17.3	A	
66	Acadia Pharmaceuticals Inc. (ACAD)	17.6	A/B	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(18.5%)	8.0%	31
Distance from 52-week high	(62.9%)	(31.4%)	15
EBIT to enterprise value	(25.6%)	(1.5%)	21
Free cash flow yield	(9.6%)	(1.0%)	31
Book value to price	1.31	0.28	92
Sales to price	0.67	0.31	75
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(0.42)	(0.14)	31

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$13.4M
Operating cash flow, four quarters	-\$22.7M
Months of runway	7.0

Days since last periodic filing

65 (10-Q received Aug 5, 2026)

Median daily dollar volume, 63 sessions

\$4.3M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	\$103.0M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
2	assets	us-gaap:Assets	\$311.8M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
3	operating income	us-gaap:OperatingIncomeLoss	-\$50.1M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$148.6M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
5	income tax	us-gaap:IncomeTaxExpenseBenefit	\$20,000	2023-12-31	2026-02-25	10-K	0001193125-26-071775
6	total debt	us-gaap:LongTermDebt	\$0	2023-12-31	2024-02-28	10-K	0000950170-24-022073
7	book equity	us-gaap:StockholdersEquity	\$160.4M	2023-12-31	2025-02-25	10-K	0000950170-25-026681
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$9.7M	2023-12-31	2025-02-25	10-K	0000950170-25-026681
9	total debt	us-gaap:LongTermDebt	\$40.2M	2022-12-31	2024-02-28	10-K	0000950170-24-022073
10	book equity	us-gaap:StockholdersEquity	\$89.9M	2022-12-31	2024-02-28	10-K	0000950170-24-022073
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$11.8M	2022-12-31	2024-02-28	10-K	0000950170-24-022073
12	net income	us-gaap:NetIncomeLoss	-\$38.9M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$15.5M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
14	assets	us-gaap:Assets	\$318.6M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$134.5M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
16	gross profit	us-gaap:GrossProfit	\$98.9M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$139.9M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
18	gross profit	us-gaap:GrossProfit	\$53.8M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$89.1M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
20	gross profit	us-gaap:GrossProfit	\$21.3M	2022-12-31	2025-02-25	10-K	0000950170-25-026681
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$49.0M	2022-12-31	2025-02-25	10-K	0000950170-25-026681
22	gross profit	us-gaap:GrossProfit	\$4.5M	2021-12-31	2023-03-06	10-K	0000950170-23-006237
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$22.6M	2021-12-31	2023-03-06	10-K	0000950170-23-006237
24	current assets	us-gaap:AssetsCurrent	\$287.5M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
25	current liabilities	us-gaap:LiabilitiesCurrent	\$26.3M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$661.0M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
27	operating income	us-gaap:OperatingIncomeLoss	-\$48.2M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
28	book equity	us-gaap:StockholdersEquity	\$275.7M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
29	liabilities	us-gaap:Liabilities	\$36.1M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$4.1M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
31	interest expense	us-gaap:InterestExpense	\$19,000	2025-12-31	2026-02-25	10-K	0001193125-26-071775
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$3.8M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
33	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$16.9M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$5.4M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
35	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$41.6M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
36	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$4.8M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
37	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$58.9M	2022-12-31	2025-02-25	10-K	0000950170-25-026681
38	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$2.4M	2022-12-31	2025-02-25	10-K	0000950170-25-026681
39	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$3.3M	2025-12-31	2026-02-25	10-K	0001193125-26-071775
40	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$138.9M	2023-12-31	2026-02-25	10-K	0001193125-26-071775
41	income tax	us-gaap:IncomeTaxExpenseBenefit	\$66,000	2025-12-31	2026-02-25	10-K	0001193125-26-071775
42	current assets	us-gaap:AssetsCurrent	\$293.8M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
43	current liabilities	us-gaap:LiabilitiesCurrent	\$25.9M	2024-12-31	2026-02-25	10-K	0001193125-26-071775
44	assets	us-gaap:Assets	\$182.6M	2023-12-31	2025-02-25	10-K	0000950170-25-026681
45	assets	us-gaap:Assets	\$150.2M	2022-12-31	2024-02-28	10-K	0000950170-24-022073
46	shares outstanding	dei:EntityCommonStockSharesOutstanding	41,266,335	2026-02-18	2026-02-25	10-K	0001193125-26-071775
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,490,542	2025-02-14	2025-02-25	10-K	0000950170-25-026681